申请人:Fleming Paul
公开号:US20070066823A1
公开(公告)日:2007-03-22
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
本发明涉及由结构式I所表示的化合物,这些化合物可以结合CCR9受体并阻止配体(例如TECK)与受体的结合。本发明还涉及一种抑制CCR9功能的方法,以及在研究、治疗、预防和诊断方法中使用结构式I所表示的化合物。